Safety and immunogenicity of different booster vaccination schemes for COVID-19 used in El Salvador

Autores
Sandoval, Xochitl; Domínguez, Rhina; Recinos, Delmy; Zelaya, Susana; Cativo, Patricia; Docena, Guillermo H.
Año de publicación
2024
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Purpose. The effectiveness of COVID-19 vaccination schemes and the combination of vaccines of various platforms for administering booster doses is still being studied since it will depend on the population response to vaccines. We aimed to evaluate the safety, protection and immunogenicity of the Salvadorean population´s third dose booster COVID-19 vaccine and the potential benefit of homologous vs heterologous regimens.Materials and methods. This is an analytical observational cohort study in a population aged 18 to 65 that was primarily vaccinated with AstraZeneca, Sinovac or Pfizer/BioNTech. Volunteers were recruited (n=223) and followed up for 3 months after receiving the 3rd vaccine (BNT162b2) as a booster. Adverse reactions were monitored, serum anti-Spike IgG was assessed by chemiluminescence and PCR was carried out when subjects developed clinical signs. Results. The cohorts finally included 199 participants and we observed only mild adverse effects in all cohorts. A significant increase in specific IgG levels was found after the booster dose in all cohorts. The heterologous scheme with Sinovac showed the greatest increase in antibody titer and a decrease was observed in all participants after 3 months. During the follow-up period, 30 participants showed symptomatology compatible with COVID-19, but only 4 were laboratory-confirmed and they showed mild clinical signs. Conclusion. These findings indicate that the booster dose used were safe and promoted an immediate increase in immunogenicity that decreased over time. The heterologous regimen showed stronger immunogenicity than the mRNA-based homologous scheme.
Fil: Sandoval, Xochitl. Instituto Nacional de Salud de El Salvador; El Salvador
Fil: Domínguez, Rhina. Instituto Nacional de Salud de El Salvador; El Salvador
Fil: Recinos, Delmy. Instituto Nacional de Salud de El Salvador; El Salvador
Fil: Zelaya, Susana. Instituto Nacional de Salud de El Salvador; El Salvador
Fil: Cativo, Patricia. Instituto Nacional de Salud de El Salvador; El Salvador
Fil: Docena, Guillermo H.. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata. Instituto de Estudios Inmunológicos y Fisiopatológicos. Universidad Nacional de La Plata. Facultad de Ciencias Exactas. Instituto de Estudios Inmunológicos y Fisiopatológicos; Argentina
Materia
COVID-19
VACCINE
SARS-CoV-2
IMMUNOGENICITY
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/265243
Acceder
id CONICETDig_9288f0a945b802d72227e452ef81e210
oai_identifier_str oai:ri.conicet.gov.ar:11336/265243
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Safety and immunogenicity of different booster vaccination schemes for COVID-19 used in El SalvadorSandoval, XochitlDomínguez, RhinaRecinos, DelmyZelaya, SusanaCativo, PatriciaDocena, Guillermo H.COVID-19VACCINESARS-CoV-2IMMUNOGENICITYhttps://purl.org/becyt/ford/1.6https://purl.org/becyt/ford/1Purpose. The effectiveness of COVID-19 vaccination schemes and the combination of vaccines of various platforms for administering booster doses is still being studied since it will depend on the population response to vaccines. We aimed to evaluate the safety, protection and immunogenicity of the Salvadorean population´s third dose booster COVID-19 vaccine and the potential benefit of homologous vs heterologous regimens.Materials and methods. This is an analytical observational cohort study in a population aged 18 to 65 that was primarily vaccinated with AstraZeneca, Sinovac or Pfizer/BioNTech. Volunteers were recruited (n=223) and followed up for 3 months after receiving the 3rd vaccine (BNT162b2) as a booster. Adverse reactions were monitored, serum anti-Spike IgG was assessed by chemiluminescence and PCR was carried out when subjects developed clinical signs. Results. The cohorts finally included 199 participants and we observed only mild adverse effects in all cohorts. A significant increase in specific IgG levels was found after the booster dose in all cohorts. The heterologous scheme with Sinovac showed the greatest increase in antibody titer and a decrease was observed in all participants after 3 months. During the follow-up period, 30 participants showed symptomatology compatible with COVID-19, but only 4 were laboratory-confirmed and they showed mild clinical signs. Conclusion. These findings indicate that the booster dose used were safe and promoted an immediate increase in immunogenicity that decreased over time. The heterologous regimen showed stronger immunogenicity than the mRNA-based homologous scheme.Fil: Sandoval, Xochitl. Instituto Nacional de Salud de El Salvador; El SalvadorFil: Domínguez, Rhina. Instituto Nacional de Salud de El Salvador; El SalvadorFil: Recinos, Delmy. Instituto Nacional de Salud de El Salvador; El SalvadorFil: Zelaya, Susana. Instituto Nacional de Salud de El Salvador; El SalvadorFil: Cativo, Patricia. Instituto Nacional de Salud de El Salvador; El SalvadorFil: Docena, Guillermo H.. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata. Instituto de Estudios Inmunológicos y Fisiopatológicos. Universidad Nacional de La Plata. Facultad de Ciencias Exactas. Instituto de Estudios Inmunológicos y Fisiopatológicos; ArgentinaKorean Vaccine Society2024-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/265243Sandoval, Xochitl; Domínguez, Rhina; Recinos, Delmy; Zelaya, Susana; Cativo, Patricia; et al.; Safety and immunogenicity of different booster vaccination schemes for COVID-19 used in El Salvador; Korean Vaccine Society; Clinical and Experimental Vaccine Research; 13; 1; 1-2024; 1-72287-366XCONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.7774/cevr.2024.13.1.35info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-10-15T15:45:47Zoai:ri.conicet.gov.ar:11336/265243instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-10-15 15:45:47.758CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Safety and immunogenicity of different booster vaccination schemes for COVID-19 used in El Salvador
title Safety and immunogenicity of different booster vaccination schemes for COVID-19 used in El Salvador
spellingShingle Safety and immunogenicity of different booster vaccination schemes for COVID-19 used in El Salvador
Sandoval, Xochitl
COVID-19
VACCINE
SARS-CoV-2
IMMUNOGENICITY
title_short Safety and immunogenicity of different booster vaccination schemes for COVID-19 used in El Salvador
title_full Safety and immunogenicity of different booster vaccination schemes for COVID-19 used in El Salvador
title_fullStr Safety and immunogenicity of different booster vaccination schemes for COVID-19 used in El Salvador
title_full_unstemmed Safety and immunogenicity of different booster vaccination schemes for COVID-19 used in El Salvador
title_sort Safety and immunogenicity of different booster vaccination schemes for COVID-19 used in El Salvador
dc.creator.none.fl_str_mv Sandoval, Xochitl
Domínguez, Rhina
Recinos, Delmy
Zelaya, Susana
Cativo, Patricia
Docena, Guillermo H.
author Sandoval, Xochitl
author_facet Sandoval, Xochitl
Domínguez, Rhina
Recinos, Delmy
Zelaya, Susana
Cativo, Patricia
Docena, Guillermo H.
author_role author
author2 Domínguez, Rhina
Recinos, Delmy
Zelaya, Susana
Cativo, Patricia
Docena, Guillermo H.
author2_role author
author
author
author
author
dc.subject.none.fl_str_mv COVID-19
VACCINE
SARS-CoV-2
IMMUNOGENICITY
topic COVID-19
VACCINE
SARS-CoV-2
IMMUNOGENICITY
purl_subject.fl_str_mv https://purl.org/becyt/ford/1.6
https://purl.org/becyt/ford/1
dc.description.none.fl_txt_mv Purpose. The effectiveness of COVID-19 vaccination schemes and the combination of vaccines of various platforms for administering booster doses is still being studied since it will depend on the population response to vaccines. We aimed to evaluate the safety, protection and immunogenicity of the Salvadorean population´s third dose booster COVID-19 vaccine and the potential benefit of homologous vs heterologous regimens.Materials and methods. This is an analytical observational cohort study in a population aged 18 to 65 that was primarily vaccinated with AstraZeneca, Sinovac or Pfizer/BioNTech. Volunteers were recruited (n=223) and followed up for 3 months after receiving the 3rd vaccine (BNT162b2) as a booster. Adverse reactions were monitored, serum anti-Spike IgG was assessed by chemiluminescence and PCR was carried out when subjects developed clinical signs. Results. The cohorts finally included 199 participants and we observed only mild adverse effects in all cohorts. A significant increase in specific IgG levels was found after the booster dose in all cohorts. The heterologous scheme with Sinovac showed the greatest increase in antibody titer and a decrease was observed in all participants after 3 months. During the follow-up period, 30 participants showed symptomatology compatible with COVID-19, but only 4 were laboratory-confirmed and they showed mild clinical signs. Conclusion. These findings indicate that the booster dose used were safe and promoted an immediate increase in immunogenicity that decreased over time. The heterologous regimen showed stronger immunogenicity than the mRNA-based homologous scheme.
Fil: Sandoval, Xochitl. Instituto Nacional de Salud de El Salvador; El Salvador
Fil: Domínguez, Rhina. Instituto Nacional de Salud de El Salvador; El Salvador
Fil: Recinos, Delmy. Instituto Nacional de Salud de El Salvador; El Salvador
Fil: Zelaya, Susana. Instituto Nacional de Salud de El Salvador; El Salvador
Fil: Cativo, Patricia. Instituto Nacional de Salud de El Salvador; El Salvador
Fil: Docena, Guillermo H.. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata. Instituto de Estudios Inmunológicos y Fisiopatológicos. Universidad Nacional de La Plata. Facultad de Ciencias Exactas. Instituto de Estudios Inmunológicos y Fisiopatológicos; Argentina
description Purpose. The effectiveness of COVID-19 vaccination schemes and the combination of vaccines of various platforms for administering booster doses is still being studied since it will depend on the population response to vaccines. We aimed to evaluate the safety, protection and immunogenicity of the Salvadorean population´s third dose booster COVID-19 vaccine and the potential benefit of homologous vs heterologous regimens.Materials and methods. This is an analytical observational cohort study in a population aged 18 to 65 that was primarily vaccinated with AstraZeneca, Sinovac or Pfizer/BioNTech. Volunteers were recruited (n=223) and followed up for 3 months after receiving the 3rd vaccine (BNT162b2) as a booster. Adverse reactions were monitored, serum anti-Spike IgG was assessed by chemiluminescence and PCR was carried out when subjects developed clinical signs. Results. The cohorts finally included 199 participants and we observed only mild adverse effects in all cohorts. A significant increase in specific IgG levels was found after the booster dose in all cohorts. The heterologous scheme with Sinovac showed the greatest increase in antibody titer and a decrease was observed in all participants after 3 months. During the follow-up period, 30 participants showed symptomatology compatible with COVID-19, but only 4 were laboratory-confirmed and they showed mild clinical signs. Conclusion. These findings indicate that the booster dose used were safe and promoted an immediate increase in immunogenicity that decreased over time. The heterologous regimen showed stronger immunogenicity than the mRNA-based homologous scheme.
publishDate 2024
dc.date.none.fl_str_mv 2024-01
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/265243
Sandoval, Xochitl; Domínguez, Rhina; Recinos, Delmy; Zelaya, Susana; Cativo, Patricia; et al.; Safety and immunogenicity of different booster vaccination schemes for COVID-19 used in El Salvador; Korean Vaccine Society; Clinical and Experimental Vaccine Research; 13; 1; 1-2024; 1-7
2287-366X
CONICET Digital
CONICET
url http://hdl.handle.net/11336/265243
identifier_str_mv Sandoval, Xochitl; Domínguez, Rhina; Recinos, Delmy; Zelaya, Susana; Cativo, Patricia; et al.; Safety and immunogenicity of different booster vaccination schemes for COVID-19 used in El Salvador; Korean Vaccine Society; Clinical and Experimental Vaccine Research; 13; 1; 1-2024; 1-7
2287-366X
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.7774/cevr.2024.13.1.35
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Korean Vaccine Society
publisher.none.fl_str_mv Korean Vaccine Society
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1846083556821958656
score 13.22299

Publicaciones similares